Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer (TA404)

Technology Appraisal Guidance No. 404

Source: National Institute for Health and Care Excellence

1. Guidance

1.1 Degarelix is recommended as an option for treating advanced hormone-dependent prostate cancer in people with spinal metastases, only if the commissioner can achieve at least the same discounted drug cost as that available to the NHS in June 2016.

1.2 This guidance is not intended to affect the position of patients whose treatment with degarelix was started within the NHS before this guidance was published. Treatment of those patients may continue without change to whatever funding arrangements were in place for them before this guidance was published until they and their NHS clinician consider it appropriate to stop.


    The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at

    This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

    © Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

    Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email:

    Degarelix for treating advanced hormone-dependent prostate cancer 

    Issue Date: August 2016

    MIMS Clinics

    Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

    Register or Subscribe to MIMS

    GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

    Register or subscribe

    MIMS bulletins

    News and updates straight to your inbox.

    Prescribing Update: Fortnightly news bulletin
    Urgent prescribing updates
    Spotlight: Disease-themed monthly round-up

    Sign me up

    MIMS Dermatology

    Read the latest issue online exclusively on MIMS Learning.

    Read MIMS Dermatology

    Mobile apps

    MIMS: access the full drug database and quick-reference tables on the go

    MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

    Promo Image

    Clinical calculators

    Handy calculators and conversions for primary care.